Caught Out By Arcus Biosciences' Slide? Here's What Bears Saw
Arcus Biosciences experienced a 29.6% loss for shareholders since the start of the year, despite promising kidney cancer data and a long cash runway. Investors weighed optimistic outlooks, predicting a 19% increase in Fair Value based on drug development and funding, against cautious views highlighting reliance on partnerships and regulatory risks, which suggested a 50% decrease in Fair Value. The company's recent performance showed mixed signals, with collaboration revenue dropping and Gilead opting out of a partnership payment, leaving profitability hopes unproven.
RCUS: Casdatifan’s RCC program advances toward first-line Phase III and an early-2028 PEAK-1 readout
Arcus Biosciences, Inc. (RCUS) is prioritizing the development of Casdatifan, with enrollment for the PEAK-1 study expected to conclude within one to two months, and a PFS readout anticipated in early 2028. The company plans to initiate a first-line Phase III trial by the end of 2026, with initial patient enrollment projected for early 2027. This information is based on an audio transcript from the Jefferies Global Healthcare Conference on November 16, 2026.
Arcus Biosciences stock hits 52-week low at $17.43 By Investing.com
Arcus Biosciences Inc (RCUS) stock has fallen to a new 52-week low of $17.43, reflecting a challenging year with an 11.46% decline. Despite this, several analysts have recently reiterated Buy or Outperform ratings with price targets up to $50, citing the potential of its casdatifan drug for renal cell carcinoma. However, InvestingPro Tips indicate that the company is burning cash quickly and the stock is considered overvalued.
Arcus Biosciences stock hits 52-week low at $17.43 By Investing.com
Arcus Biosciences (RCUS) stock has fallen to a 52-week low of $17.43, with shares currently trading at $17.09, reflecting a 1-year change of -11.46% and a significant decline over the past six months and year-to-date. InvestingPro Tips highlight concerns such as downward earnings revisions by analysts, rapid cash burn, and an "overvalued" assessment based on Fair Value analysis, leading to a "WEAK" overall financial health score. Despite these challenges, several analysts have recently issued positive ratings and increased price targets, citing promising data for the company's casdatifan drug in renal cell carcinoma.
Arcus Biosciences Stock Faces Revenue Drop And Wider Nine Month Loss
Arcus Biosciences (NYSE:RCUS) reported a significant revenue drop in Q3 2026 to US$9 million from US$26 million a year earlier, and a net loss of US$128 million. For the first nine months of 2026, the company recorded US$67 million in revenue and a US$347 million net loss, highlighting increased cash burn as it focuses on late-stage oncology programs like casdatifan. The investment narrative hinges on the success of its oncology pipeline justifying current high spending, with analysts projecting positive earnings by 2029, though more bearish outlooks exist.
Arcus Biosciences, Inc. (RCUS) stock price, news, quote and history
This article provides a comprehensive overview of Arcus Biosciences, Inc. (RCUS), detailing its stock performance, financial data, and clinical-stage biopharmaceutical developments. It covers key metrics like market cap, P/E ratio, and earnings, alongside an overview of its drug pipeline including Casdatifan, Domvanalimab, and Quemliclustat for various cancers. The report also includes analyst insights, price targets, and a comparison of RCUS's trailing total returns against the S&P 500 benchmark.
Arcus Biosciences, Inc. (RCUS) stock price, news, quote and history
Arcus Biosciences, Inc. (RCUS) closed at $18.28, up 3.34% on November 6, 2026. The clinical-stage biopharmaceutical company focuses on developing cancer therapies, with a portfolio including Casdatifan, Domvanalimab, and Zimberelimab. Analysts have an average 1-year target price of $40.83, with recent ratings maintaining an Outperform stance and raising price targets.
Arcus Biosciences stock trades at 17.69 US dollars after-hours
Arcus Biosciences stock (RCUS) traded at $17.69 after-hours on November 5, 2026, providing an updated market reference for investors. The clinical-stage biotechnology company specializes in developing cancer and immune-disease therapies, with its lead program, casdatifan, targeting kidney cancer. Arcus Biosciences is based in Hayward, California, and collaborates with AstraZeneca on several clinical development programs.
Leerink Partners maintains Arcus Biosciences at Outperform, raises price target to $49 from $46
Leerink Partners has maintained its "Outperform" rating for Arcus Biosciences and increased its price target to $49 from $46, representing a 6.5% raise. This new price target suggests an impressive 153.8% upside from the stock's closing price of $19.31 on November 4th. Other recent analyst actions for Arcus Biosciences show price targets ranging from $40 to $50.
Arcus Biosciences, Inc. (RCUS) stock price, news, quote and history
Arcus Biosciences, Inc. (RCUS) is a clinical-stage biopharmaceutical company focused on developing cancer therapies. The article provides current stock information, including a price of $18.38, a 3.90% increase, and a market cap of $2.647 billion. It details the company's product pipeline, financial performance, and analyst ratings, noting an average 1-year target estimate of $41.00.
Arcus Biosciences (RCUS) Stock May Be Fully Priced For Its Sales Potential
Arcus Biosciences (RCUS) stock has seen a significant 50.4% decline over the past five years, prompting questions about whether its current valuation is justified by existing and potential sales. The company's P/S ratio of 23.7x is higher than the biotech industry average, suggesting that its current price factors in a rich set of expectations for its pipeline and future execution. Investors need to weigh the comfort of paying this sales multiple against the company's prospects and inherent risks.
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Lags Revenue Estimates
Arcus Biosciences (RCUS) reported a wider-than-expected Q3 loss of $1 per share, missing the Zacks Consensus Estimate of $0.92 per share, and also fell short on revenue expectations with $9 million against an anticipated $11.9 million. The company's shares have dropped 20.7% year-to-date, and its unfavorable estimate revisions trend has led to a Zacks Rank #4 (Sell), suggesting potential underperformance in the near future.
Arcus Biosciences earnings missed by $0.12, revenue fell short of estimates
Arcus Biosciences (NYSE: RCUS) reported third-quarter EPS of $-1.00, missing analyst estimates by $0.12, and revenue of $9M, which was slightly below the consensus estimate of $9.03M. The company's stock price closed at $19.31, reflecting a decline of -32.53% over the last 3 months and -2.23% over the last 12 months. InvestingPro rates Arcus Biosciences's financial health as "weak performance."
Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline Update
Arcus Biosciences reported a net loss of $128 million for the third quarter of 2026, a slight improvement from $135 million in the same period of 2025. The company highlighted significant progress in its casdatifan development strategy for kidney cancer, with enrollment nearing completion for the PEAK-1 Phase 3 study and PEAK-20 expected to initiate by year-end 2026. Arcus also announced a strong financial position, with $694 million in cash, cash equivalents, and marketable securities, plus $288 million from an October equity financing, providing a cash runway into 2029.
(RCUS) Price Dynamics and Execution-Aware Positioning
This article provides an analysis of Arcus Biosciences Inc. (NASDAQ: RCUS) stock, highlighting divergent sentiment across different time horizons and elevated downside risk. It presents three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis indicating support and resistance levels. The analysis suggests choppy conditions ahead for the stock.
What Investors Got Wrong About Arcus Biosciences Before The Drop
Arcus Biosciences (NYSE:RCUS) has seen a 23.4% stock drop in 2026 due to widening losses and mixed trial results. Investors had to choose between optimistic and pessimistic outlooks; the optimistic view, valuing the stock at US$28.45, focused on casdatifan's late-stage development in renal cell carcinoma (RCC) and projected profit, while the pessimistic view, at US$12, highlighted partnership dependency and revenue decline. The company's recent focus on casdatifan in RCC trials supports the optimistic case, but falling revenue and growing losses mean profitability remains unproven.
What Investors Got Wrong About Arcus Biosciences Before The Drop
Arcus Biosciences experienced a 23.4% loss in 2026, primarily due to widening losses and mixed trial updates. Investors faced two narratives: an optimistic one valuing the company higher based on casdatifan's potential and a bearish view focusing on partner dependency and revenue decline. The company's recent focus on casdatifan for renal cell carcinoma trials has been a key development, supporting the bullish case despite a significant drop in Q2 revenue and reported losses.
Arcus Biosciences to Participate in the Jefferies Global Healthcare Conference 2026 in London
Arcus Biosciences announced that its management team will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Monday, November 16th, 2026, at 5:00 PM GMT. A live webcast and replay of the presentation will be available on the company's website. Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and immune diseases.
Arcus Biosciences, Inc. (RCUS) Seasonal Returns Chart - Yahoo Finance
The article provides a seasonal returns chart for Arcus Biosciences, Inc. (RCUS), displaying the average monthly price return from 2018 to 2026. It also includes current stock information, showing RCUS trading at $18.19 with a slight decline. The page is from Yahoo Finance and offers various financial data points for the company.
Learn Why The Bull Case For Arcus Biosciences Stock Could Change Following Kidney Cancer Data
Arcus Biosciences recently completed a US$250.0 million equity offering and released detailed ARC-20 data for its HIF-2a inhibitor casdatifan in clear cell renal cell carcinoma, showing favorable efficacy and safety compared to benchmarks. This data, alongside the new funding, could significantly alter the investment outlook for the company by clarifying pipeline priorities, trial designs, and long-term funding strategies. The article explores how these developments might impact Arcus Biosciences' valuation and future prospects in oncology.
Citi Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $50
Citi has reiterated its Buy rating for Arcus Biosciences (RCUS.US) and maintained a target price of $50. This indicates a continued positive outlook from the firm regarding the biotechnology company's stock performance.
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. announced that its Compensation Committee granted new employment inducement options and restricted stock units to three new employees. These awards include options to purchase 10,650 shares and restricted stock units for 5,350 shares, granted under the company's 2020 Inducement Plan. The company is a clinical-stage biopharmaceutical firm focused on developing cancer and immune disease therapies.
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSE: RCUS) announced that its Compensation Committee granted equity awards to three new employees. These grants include options to purchase 10,650 common shares at an exercise price of $18.54 and restricted stock units for an additional 5,350 shares. The awards were issued under the company's 2020 Inducement Plan, consistent with NYSE rules for new employee incentives.
Arcus Biosciences, Inc. Estimates – NYSE:RCUS
This article from TradingView provides an overview of Arcus Biosciences, Inc. (NYSE: RCUS) financial data and analyst estimates. It highlights sections for exploring reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics, allowing users to compare actual results with average, high, and low estimates and visualize trends over time. The platform also offers tools like Supercharts, Screeners, and various calendars, alongside community and educational resources.
Arcus Biosciences Closes $269.7 Million Stock Offering
Arcus Biosciences (RCUS) has successfully completed a public offering, selling 16.4 million shares at $17.50 each, including the underwriters' full exercise of their option for additional shares. This offering generated approximately $269.7 million in net proceeds for the company.
Form 424B5 Arcus Biosciences Inc For: 22 October By Investing.com
This article reports on the filing of Form 424B5 by Arcus Biosciences Inc., referencing the document for October 22. It mentions the stock symbol RCUS, which experienced a 1.36% increase. The content is brief and primarily serves as a notification of the SEC filing.
Arcus Biosciences announces public stock offering
Arcus Biosciences (RCUS) has initiated an underwritten public offering of its common stock, with the company selling all shares. The underwriters have a 30-day option to purchase an additional 15% of the shares offered. This announcement pertains to a public stock offering by the biotechnology company.
Watkins Advises Arcus Biosciences on US$250 Million Public Offering of Common Stock
Latham & Watkins LLP advised Arcus Biosciences, Inc. (NYSE: RCUS) on its US$250 million underwritten public offering of common stock. Arcus Biosciences, a biopharmaceutical company, priced 14,285,715 shares at US$17.50 per share, with an option for underwriters to purchase additional shares. The offering is expected to close on October 23, 2026.
Arcus Biosciences, Inc. (RCUS) Discusses New Data on Casdatifan for Kidney Cancer Across Multiple Lines of Therapy - Slideshow (NYSE:RCUS)
Arcus Biosciences, Inc. (RCUS) presented new data on its drug candidate, Casdatifan, for the treatment of kidney cancer across various lines of therapy. This information was shared via a slide deck published by the company. The article was prepared by Seeking Alpha's transcripts team, which focuses on providing earnings call transcripts and related developments.
Arcus Biosciences reports $694M cash for pipeline advancement through pivotal trials
Arcus Biosciences concluded the third quarter with approximately $694 million in cash, cash equivalents, and marketable securities, providing substantial liquidity to advance its pipeline through critical clinical readouts. The company's key programs, including the Phase 3 PRISM-1 trial for quemliclustat in pancreatic cancer and multiple late-stage combination studies for zimberelimab in oncology, are capital-intensive. This cash position is crucial as the company seeks to generate proof-of-concept data for its adenosine axis therapies, a scientific thesis that remains largely unvalidated at the regulatory level in oncology, without needing an immediate equity raise.
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
Arcus Biosciences, Inc. announced the pricing of an underwritten public offering of 14,285,715 shares of its common stock at $17.50 per share, expected to generate $250.0 million in gross proceeds. The company has also granted underwriters a 30-day option to purchase additional shares. The offering is anticipated to close on October 23, 2026, with Jefferies, Leerink Partners, TD Cowen, Evercore ISI, and Mizuho acting as joint book-running managers.
Arcus Biosciences Sees $5B-$10B RCC Opportunity for Casdatifan at Investor Day
Arcus Biosciences outlined a potential $5 billion to $10 billion commercial opportunity for its investigational HIF-2 alpha inhibitor, casdatifan, in renal cell carcinoma (RCC). The company presented updated clinical data across various treatment lines, highlighting differentiated pharmacodynamic activity compared to another HIF-2 alpha inhibitor and plans for several Phase III studies. Casdatifan showed promising survival signals and objective response rates in earlier trials, with ongoing and planned studies to further evaluate its efficacy in combination therapies.
Arcus Biosciences stock falls on public offering announcement
Arcus Biosciences Inc. (NYSE: RCUS) shares fell 6.6% in after-hours trading and 20% during regular trading after the company announced an underwritten public offering of common stock. The offering will grant underwriters a 30-day option to purchase an additional 15% of shares. Citi analyst Yigal Nochomovitz maintained a Buy rating and $50.00 price target, noting the decline was influenced by the offering and clinical trial results showing a 14.5-month median progression-free survival, aligning with expectations.
Citi reiterates buy rating on Arcus Biosciences after stock drops 20%
Citi analyst Yigal Nochomovitz reiterated a Buy rating and $50.00 price target on Arcus Biosciences (NYSE: RCUS) despite a 20% drop in share price. The decline was attributed to a follow-on offering and market expectations for a 2L mPFS of at least 15 months, although the reported 14.5 months was comparable to a similar trial. Nochomovitz noted the comparable outcome was significant as the 14.5-month result did not exclude prior-lenva patients, who typically have poorer outcomes.
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm
Kuehn Law, PLLC is investigating Arcus Biosciences, Inc. (NYSE: RCUS) officers and directors for potential breaches of fiduciary duties related to self-dealing. The firm is encouraging long-term shareholders to contact them to discuss potential damages and corporate governance reforms, emphasizing that participation is free and without obligation.
Arcus Biosciences Drops 5.5% After Truist Securities Maintains Buy
Arcus Biosciences (RCUS) shares fell 5.5% despite several positive analyst upgrades, including Truist Securities maintaining a "Buy" rating and raising its price target. Wedbush and William Blair also reiterated "Outperform" ratings, with the average new price target across these firms implying a double from current trading levels. The market's reaction, characterized by a decline in stock price on typical trading volume, suggests investors may be taking profits or reacting to broader sector trends, despite analyst confidence in the biotech firm's pipeline.
Arcus Biosciences slides 20% on stock offering, kidney-cancer data (RCUS:NYSE)
Arcus Biosciences shares tumbled nearly 20% following the presentation of new clinical data for its lead oncology candidate, casdatifan, in kidney cancer treatment, coupled with an announced public stock offering. While the clinical data showed a 50% confirmed response rate, analysts raised concerns about small trial sizes, the need for Phase 3 confirmation, and overall valuation risks. The decline reflects investor apprehension despite the promising early efficacy signals.
Truist Securities maintains Buy rating on Arcus Biosciences, $41 price target
Truist Securities has reiterated its Buy rating on Arcus Biosciences with a $41 price target, representing a potential 72.6% upside. The positive outlook is driven by strong clinical data from product candidates like Cas + Cabo, demonstrating competitive efficacy. The company also boasts a robust pipeline with multiple Phase III programs, projecting significant revenue growth to an estimated $3.2 billion.
Arcus Biosciences prices $250 million stock offering at $17.50
Arcus Biosciences Inc. announced the pricing of an underwritten public offering of 14,285,715 shares of common stock at $17.50 per share, aiming to raise $250.0 million. The biopharmaceutical company has also granted underwriters a 30-day option to purchase additional shares. The offering is expected to close on Friday, with Jefferies, Leerink Partners, TD Cowen, Evercore ISI, and Mizuho serving as joint book-running managers.
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
Arcus Biosciences, a late clinical-stage biopharmaceutical company, announced the pricing of a $250 million public offering of 14,285,715 shares of its common stock at $17.50 per share. The company has also granted underwriters a 30-day option to purchase an additional 2,142,857 shares. The offering is expected to close on October 23, 2026, with Jefferies, Leerink Partners, TD Cowen, Evercore ISI, and Mizuho acting as joint book-running managers.
Form 8K Arcus Biosciences Inc For: 20 October By Investing.com
This article reports that Arcus Biosciences Inc. filed a Form 8K on October 20, 2026. The stock symbol for Arcus Biosciences is RCUS, which saw a 7.27% increase. The article provides only the headline and the company's stock performance without further details of the filing.
Arcus Biosciences Stock In Focus After Kidney Cancer Trial Update
Arcus Biosciences released new clinical results for casdatifan in clear cell renal cell carcinoma, showing progression-free survival above benchmarks and no unexpected safety issues. The company plans to advance casdatifan into multiple Phase 3 programs, increasing its resource commitment and concentrating development risk in renal cancer. This strategic move could significantly shape Arcus Biosciences' investment narrative, as analysts project substantial revenue and earnings growth by 2029, though some see even greater upside potential.
Arcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney Cancer
Arcus Biosciences announced new data from its ARC-20 study, highlighting the potential of casdatifan, a HIF-2α inhibitor, as a foundational treatment across all lines of therapy for clear cell renal cell carcinoma (ccRCC). The data showed promising progression-free survival and overall survival rates when casdatifan was used alone or in combination with other therapies, exceeding established benchmarks. These results support the planned initiation of two Phase 3 registrational trials, PEAK-20 and PEAK-1, by year-end, aiming to establish casdatifan as a backbone therapy for ccRCC patients.
Biotech Stocks Make NYSE Top Gainers October 20th
Arcus Biosciences (NYSE: RCUS) was a top gainer on the NYSE, with its stock trading up more than 9% following the release of new data from its ARC-20 study. The data showed promising results for casdatifan in treating kidney cancer across various settings, exceeding third-party benchmarks. The company plans to initiate a Phase 3 study by year-end, driven by these strong clinical findings.
RCUS: Casdatifan pairs multi-line kidney cancer data with a planned Phase 3 expansion
Casdatifan, developed by Arcus Biosciences (RCUS), has shown promising early efficacy in treating kidney cancer across multiple lines, including late-line overall survival and first-line response data. The company plans a Phase 3 expansion targeting first-line and second-line settings, anticipating a market opportunity of $5B–$10B and maintaining a cash runway through at least the second half of 2028. This information is based on an AI-generated summary of an Arcus Biosciences slides release from October 20, 2026.
Kidney cancer patients went a median 14.5 months without progression or death on a combo; benchmarks were ~10 months.
Arcus Biosciences presented new data from its ARC-20 platform study for casdatifan, an investigational HIF-2α inhibitor for clear cell renal cell carcinoma (ccRCC). Key findings include a 14.5-month median progression-free survival for casdatifan plus cabozantinib in second-line treatment, exceeding benchmarks of approximately 10 months, and an unprecedented 35-month median overall survival in heavily pre-treated late-line monotherapy patients. The company plans to initiate two Phase 3 registrational trials for casdatifan in first-line and second-line ccRCC by year-end.
Missed Arcus Biosciences' Rally? Here's What Early Buyers Saw
Arcus Biosciences saw a 34.3% return over the past year, driven by progress in its casdatifan kidney cancer program despite a significant revenue drop and increased losses. While the company's clinical advancements support a bullish outlook, its financial performance and reliance on partnerships present ongoing risks that investors must weigh against its current trading price. The article advises investors to consider the trade-off between pipeline momentum and financial stability when evaluating biotech companies.
Arcus Biosciences (RCUS) And The Casdatifan Case As Fair Value Comes Into Focus
Arcus Biosciences (RCUS) stock has recently traded at US$22.82, with mixed short-term moves but a strong 37.47% one-year return. Analysts widely consider the stock 43% undervalued, projecting a fair value of US$39.91 based on ambitious growth and margin assumptions, particularly with the potential of its HIF-2 alpha inhibitor, casdatifan. However, a different view based on revenue multiples suggests significant valuation risk, as its P/S ratio of 24.8x is well above industry averages.
JPMorgan starts coverage of Arcus Biosciences stock at Overweight
JPMorgan initiated coverage of Arcus Biosciences (RCUS) with an Overweight rating and a $41.00 price target. The investment case is centered on casdatifan, an investigational HIF-2a inhibitor for renal cell carcinoma, with projected worldwide unadjusted peak sales of $4.0 billion by 2035. The company is set to present new ARC-20 data on October 20, 2026, which is a key near-term catalyst.
JPMorgan Initiates Coverage on Arcus Biosciences With Overweight Rating, $41 Price Target
JPMorgan has initiated coverage on Arcus Biosciences (NYSE:RCUS) with an Overweight rating and a price target of $41. This new coverage indicates a positive outlook from JPMorgan on the biotechnology company's future performance.